Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News IDEAYA Biosciences Inc IDYA

Healthcare Biotechnology
IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates are darovasertib (IDE196), IDE397, IDE161 and GSK101 (Pol Theta Helicase). IDE196, a small molecule protein kinase C (PKC), inhibitor, in combination with... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:IDYA)

IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance

PR Newswire 2 days ago

IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors

PR Newswire December 29, 2024

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PR Newswire December 27, 2024

IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma

PR Newswire December 17, 2024

IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers

PR Newswire December 16, 2024

IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024

PR Newswire December 11, 2024

IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer

PR Newswire December 10, 2024

IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor

PR Newswire December 9, 2024

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PR Newswire December 6, 2024
View More News ››

Opinion & Analysis (NDAQ:IDYA)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:IDYA)

(IDYA) Investment Analysis

NEWS: $IDYA (IDYA) Investment Analysis2024-11-13 01:50:00 ET Stock Traders Daily has produced this trading report using a proprietary...
whytestocks - November 13, 2024

Outperform Recommendation Issued On IDYA By RBC Capital

News; $IDYA Outperform Recommendation Issued On IDYA By RBC Capital2024-07-10 16:15:02 ET RBC Capital analyst issues OUTPERFORM...
whytestocks - July 10, 2024

IDEAYA Announces Positive Interim Phase 2 Monotherapy Expans

BREAKING NEWS: $IDYA IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First-in-Class MAT2A...
whytestocks - July 8, 2024

IDEAYA Announces Investor Webcast to Report Clinical Data Up

Just In: $IDYA IDEAYA Announces Investor Webcast to Report Clinical Data Update for IDE397 Phase 2 Monotherapy Expansion Dose in MTAP...
whytestocks - July 5, 2024

EMERGING PARADIGMS IN TREATMENT OF MELANOMA!

$IDYA $NKTR $MGNX $CTMX $ALKS Melanoma, a form of skin cancer, accounts for about 1% of skin cancers but is responsible for over 7...
AviseAnalytics - January 26, 2022
View more Bullboard ››

Coniagas Battery Metals Inc.

Coniagas Battery Metals Inc.

Coniagas Battery Metals Inc. is a Canada-based exploration and mining company. The Company is focused on nickel, copper, and ...
View More »